Challenges in Conducting Research in DMD

Video

The co-founder, president, and chief executive officer of Solid Biosciences, whose own son has DMD, discussed some challenges the company is facing.

“We've always known that clinical endpoints were going to be challenging in Duchenne... [knowing that], we designed a study that takes almost every possible endpoint into consideration. It's very exploratory. It has a number of primary and secondary end points and it is always looking at both biomarkers and clinical benefits.”

Ilan Ganot, co-founder, president, and chief executive officer of Solid Biosciences, has a personal reason for finding an effective, targeted treatment for Duchenne muscular dystrophy (DMD): his son has been diagnosed with the disease. His company is using advanced gene therapy approaches to try and fill a great unmet need for patients with the neuromuscular disease.

SGT-001, their lead program and a gene therapy transfer agent, is currently in phase 1/2 clinical trials. It has continued to show safety and efficacy in the first 8 patients dosed, and data from the first 6 patients showed that those who received a high-dose version exhibited 5% to 17.5% of normal microdystrophin expression levels by Western blot and 20% to 70% of positive muscle fibers by immunofluorescence.

In an interview with GeneTherapyLive, Ganot discussed the challenges of conducting research and studies in DMD. He also shared how a big part of the company’s focus right now is on solving manufacturing challenges for SGT-001 and future products in their pipeline.

REFERENCE
Morris CA, Clary CM, Redican S, et al. IGNITE-DMD phase I/II study of SGT-001 microdystrophin gene therapy for Duchenne muscular dystrophy. Presented at: 2021 American Society of Gene & Cell Therapy Annual Meeting; May 12-15, 2021. Abstract 263
Related Videos
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.